Product Description
Beclomethasone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. Beclomethasone is a 17alpha-hydroxy steroid that is prednisolone in which the hydrogens at the 9alpha and 16beta positions are substituted by a chlorine and a methyl group, respectively. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Beclomethasone)
Mechanisms of Action: Steroid Receptor Agonist, Immunosuppressive
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Company: Chiesi
Company Location: Europe
Company Founding Year: 1935
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Bulgaria, Canada, China, Czech Republic, Hungary, Mexico, Poland, Puerto Rico, Romania, Spain, United States
Active Clinical Trial Count: 9
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Colitis, Ulcerative|Conjunctivitis, Allergic|Spasm
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2025-521230-29-00 |
2025-521230-29-00 | P3 |
Not yet recruiting |
Conjunctivitis, Allergic |
2029-09-01 |
|||
2017-000330-61 |
BeCalCU | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2018-01-05 |
2025-06-05 |
Treatments |
|
NCT07768891 |
BT-BF-IA-â ¢ | P3 |
Recruiting |
Asthma |
2028-06-01 |
63% |
2026-08-18 |
Primary Endpoints|Treatments |
NCT04320342 |
TRITON | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2026-01-12 |
88% |
2026-09-22 |
Primary Endpoints|Start Date |
NCT05292586 |
FORCE2 | P3 |
Completed |
Asthma |
2024-06-24 |
93% |
2025-09-05 |
|
CTR20131574 |
CTR20131574 | P3 |
Active, not recruiting |
Asthma |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20131558 |
CTR20131558 | P3 |
Recruiting |
Asthma|Spasm |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20131559 |
CTR20131559 | P3 |
Recruiting |
Asthma|Spasm |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20131557 |
CTR20131557 | P3 |
Recruiting |
Spasm|Asthma |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/14/2026 |
News Article |
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. |
|
12/02/2025 |
News Article |
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol |
|
11/20/2025 |
News Article |
Intranasal Corticosteroids Market to Sustain USD 11.57 Billion by 2034, Driven by Rising Allergic Rhinitis Cases |
|
10/29/2025 |
News Article |
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol |
